and clinical course. The protocol was approved by the institutional review board or ethics committee at all 27 participating centers (Appendix S1). Written informed consent was waived because of the retrospective nature of the study, and none of the patients refused to participate in the study when contacted for follow-up.
In the main analysis, 3,813 study patients were categorized into No HF (n=2,210) and HF group (n=1,603) based on the presence of HF symptoms at enrolment, excluding 2 patients whose symptomatic status was not available. There were a few patients who had had HF symptoms once before enrolment, but did not have any at enrolment. We categorized those patients into the No HF group according to the definition. Thereafter, the HF group was further divided into 2 groups: AHF and CHF. In this process, because AHF is a syndrome with a wide range of conditions and acuteness, we avoided subjective categorization by not defining AHF solely on the basis of the mode of presentation or symptom onset. Instead, to keep consistency throughout the data collection and analyses, we defined the AHF and CHF groups according to whether or not hospitalized management was required. As a result, 790 patients who developed symptoms of HF requiring hospitalized management at enrolment were categorized into the AHF group, and 813 patients who had HF symptoms but did not require hospitalization were categorized into the CHF group (Figure 1) . The 3 groups were further and to identify the determinants of initial aortic valve replacement (AVR) strategy in patients with AHF in a large Japanese observational database of consecutive patients with severe AS.
Methods

Study Population
The study design and primary results of the CURRENT AS (Contemporary Outcomes After Surgery and Medical Treatment in Patients with Severe Aortic Stenosis) registry have been previously reported. 11 Briefly, the CURRENT AS registry is a retrospective, multicenter registry that enrolled 3,815 consecutive patients with severe AS from among 27 centers in Japan between January 2003 and December 2011. We searched the hospital database of transthoracic echocardiography patients, and enrolled consecutive patients who met the definition of severe AS (peak aortic jet velocity [Vmax] >4.0 m/s, mean aortic pressure gradient [PG] >40 mmHg, or aortic valve area [AVA] <1.0 cm 2 ) for the first time during the study period. Collection of clinical information, including symptoms (i.e., HF, angina and syncope), medical history, diagnostic imaging, laboratory markers and other patient characteristics, was conducted through hospital chart and database review. Presence of HF was confirmed at participating hospitals by reviewing the final diagnosis, HF-related signs or symptoms . Study flowchart. Patients were categorized into No HF and HF groups based on the presence of HF symptoms at enrolment, excluding 2 patients whose symptomatic status was not available. The HF group was further divided into 2 groups (CHF and AHF groups) according to the need for in-hospital management of HF. The 3 groups were further stratified by the initial treatment strategy to either initial AVR stratum or conservative stratum. AHF, acute HF; AS, aortic stenosis; AVR, aortic valve replacement; CHF, chronic HF; HF, heart failure.
were classified according to VARC (Valve Academic Research Consortium) definitions, and adjudicated by a clinical event committee. 12,13 HF hospitalization was defined as hospitalization for worsening HF requiring intravenous drug therapy. Other definitions of the clinical events have been described previously 11 , and clinical events were adjudicated by a clinical event committee (Appendix S1).
Statistical Analysis
Categorical variables are presented as numbers and percentages, and were compared with the chi-square test or Fisher's exact test. Continuous variables are expressed as the mean and standard deviation or median and interquartile range (IQR). Continuous variables were compared using Student's t test or Wilcoxon rank-sum test based on stratified by the initial treatment strategies to either the initial AVR stratum or conservative stratum. Because of the distinct clinical course of the patients who had coronary artery disease (CAD), we performed a sensitivity analysis in which patients with CAD were excluded from the entire cohort. In this analysis, the remaining patients were divided into 2 groups: AHF and No AHF rather than 3 groups to counteract the potential ambiguity of categorization of No HF and CHF groups in the main analyses. Follow-up was commenced on the day of the index echocardiography, unless specified otherwise.
Definitions of the Clinical Events
The primary outcome measures in the present analysis were all-cause death and HF hospitalization. Causes of death 
Results
Baseline Characteristics
According to the baseline characteristics of the 3 groups, patients in the AHF group were characterized by older age, smaller body mass index (BMI), and higher prevalence of women, untreated significant coronary artery stenosis, prior myocardial infarction, atrial fibrillation/flutter, renal dysfunction, and anemia ( Table 1) . The values for B-type natriuretic peptide (BNP) level obtained in 1,824 patients were significantly higher in the AHF group than in the CHF and No HF groups ( Table 1) . Proportion of patients with chest pain was not different among the 3 groups, although patients with syncope were more often found in the No HF group. Regarding the echocardiographic parameters, the prevalence of very severe AS, defined as Vmax ≥5 m/s, was higher in the CHF and AHF groups than in the No HF group. The AHF group had lower left ventricular ejection fraction (LVEF), higher prevalence of concomitant valvular diseases, and higher tricuspid regurgitation pressure gradient (TRPG) than the CHF and No HF groups ( Table 1 ). In terms of clinical presentation, 81% of patients in the AHF group were in NYHA class III or IV, 14% required respiratory support and 10% required their distributions. Independent risk factors for developing AHF and determinants of initial AVR strategy were identified among clinically relevant factors by means of univariate and multivariable logistic regression analyses, following the dichotomization of continuous variables by median values or clinically meaningful reference values. The risk factors for developing AHF in the entire cohort were analyzed by dividing the entire cohort into 2 groups: AHF (n=790) and No AHF (a combined group of CHF and No HF groups: n=3,023). The results are expressed as odds ratios (ORs) and their 95% confidence intervals (CIs).
Cumulative incidences of clinical events were estimated by the Kaplan-Meier method, and the differences among the groups were assessed with the log-rank test. The risks of AHF relative to No HF and CHF, respectively, for the clinical endpoints were estimated by Cox proportional hazard models and expressed as hazard ratios (HRs) and their 95% CIs. In consistent with our previous report, 11 the 21 clinically relevant factors listed in Table 1 were included as the risk-adjusting variable in the multivariable Cox proportional hazard models and the centers were incorporated as the stratification variable. All statistical analyses were performed with the statistical software program JMP 10.0.0 (SAS Institute Inc., Cary, NC, USA) or SAS 9.4 (SAS Institute). All reported P-values are 2-tailed; P<0.05 disease, and TRPG ≥40 mmHg; the negative predictors included dyslipidemia, prior history of percutaneous coronary intervention and hemodialysis ( Table 2) .
Clinical Outcomes in the Entire Cohort
Among the 1,196 patients who were assigned to an initial AVR strategy, 1,173 (98.1%) actually underwent surgical AVR (n=1,162) or transcatheter aortic valve implantation (TAVI: n=11). The median interval between the index echocardiography and the AVR procedure was 36 days (IQR: 16-61). Among the 2,617 patients who were initially assigned to a conservative strategy, 569 (21.7%) eventually underwent surgical AVR (n=541) or TAVI (n=29) with a median interval of 838 days (IQR: 307-1,308) from the index echocardiography. Therefore, during a median inotrope use.
In the entire study population, an initial AVR strategy was selected in 1,196 patients (31%), and the remaining 2,617 patients were managed conservatively. Patients in the AHF group were less often referred to an initial AVR strategy than patients in the CHF group. Surgical risk scores were significantly higher in the AHF group than in the CHF and No HF groups ( Table 1) .
Risk Factors for Developing AHF
The independent risk factors for developing AHF included advanced age, female sex, lower BMI, presence of untreated coronary artery stenosis, history of prior HF and anemia in addition to echocardiographic parameters of Vmax ≥5 m/s, LVEF <50%, coexistence of any combined valvular group than in the CHF and No HF groups, although the outcomes of AHF patients were remarkably better in the AVR stratum than those in the conservative stratum (Figure 4, Table 3 ). Even after adjusting for confounders, the excess risks of AHF relative to No HF for all-cause death and HF hospitalization remained highly significant in both the initial AVR and conservative strata ( Table 3) .
The excess adjusted risk of AHF relative to CHF remained significant for all-cause death, but was no more significant for HF hospitalization in both the initial AVR and conservative strata ( Table 3) .
Determinants of the Choice for Initial AVR Strategy in the AHF Group
Initial AVR strategy, as opposed to a conservative strategy, was more likely to be chosen for AHF patients with low surgical risk scores ( Table 4) .
Sensitivity Analysis
When patients who had CAD were excluded from the entire cohort and the remaining patients were divided into follow-up duration of 1,123 days (IQR: 559-1,577), 1743 patients (45.7%) actually underwent surgical AVR (n=1703) or TAVI (n=40). The cumulative 5-year incidence of surgical AVR or TAVI was smaller in the AHF group than in the CHF group (Figure 2A,B) . Notably, in the AHF group, surgical AVR was very rarely performed beyond 6 months after the index echocardiography. There were 17 patients for whom AVR or TAVI was performed as an emergency (no delay in providing operative intervention; n=3), urgently (surgery within 24 h of referral, n=12) or as a salvage (cardiopulmonary resuscitation en route to operating theatre or during anesthesia; n=2). Patients in the AHF group showed higher prevalence of emergency/urgent/ salvage status as compared with the other groups (0.6% vs. 0.6% vs. 2.6% in the No HF, CHF and AHF groups, respectively, P=0.02).
The cumulative incidences of all-cause death and HF hospitalization were markedly higher in the AHF group than in the CHF and No HF groups (Figure 3, Table 3 ). After adjusting confounders, the excess risks of AHF relative to CHF and No HF, respectively, for all-cause death and HF hospitalization remained highly significant ( Table 3) . Similarly, the risks for other endpoints such as cardiovascular death, aortic valve-related death, and sudden death were significantly higher in the AHF group than in the CHF and No HF groups ( Table 3) .
Clinical Outcomes According to the Initial Treatment Strategy
Regardless of the initial treatment strategy (initial AVR or conservative), the cumulative incidences of all-cause death and HF hospitalization were markedly higher in the AHF and morbidity. 5-8 Management of AHF complicating severe AS is particularly challenging because patients easily develop severe congestion or acute decline in cardiac output because of high afterload and an obstructive valve. Serious clinical conditions from multiple comorbidities may also contribute to the worse prognosis of AHF complicating severe AS. Furthermore, AHF may be evoked as a result of long-standing high afterload in the left ventricle in patients with severe AS. For those patients, irreversible pathological changes caused by high mechanical stress may lead to a sustained high risk of adverse events even after AVR. Indeed, using cardiac magnetic resonance imaging, Barone et al reported that approximately 30% of patients with AS showed focal replacement myocardial fibrosis before AVR, which had postoperative and longterm prognostic value. 14 Therefore, once AHF develops in patients with severe AS, it often leads to a dismal outcome regardless of the chosen therapeutic strategies. To improve the clinical outcomes of patients with severe AS, an early AVR strategy before emergence of AHF is warranted. (Figure S1A,B ).
Factors Associated With Development of AHF Complicating
Discussion
The main findings in the present study were as follows: (1) the prognosis of patients with severe AS complicated by AHF was poor, with extremely high rates of all-cause death and HF hospitalization; (2) AHF patients as compared with CHF patients less frequently underwent AVR, and had higher long-term mortality rates even after AVR;
(3) several clinical and echocardiographic factors were found to predispose to the development of AHF, which might help identify appropriate candidates for early AVR before the emergence of AHF. Large-scale cohort studies in this decade have demonstrated that AHF in general is disruptive with high mortality 
Study Limitations
In this study, a significant proportion of patients were enrolled as severe AS based solely on AVA <1.0 cm 2 . Those patients with low-gradient AS might well represent a heterogeneous population in whom the indication of AVR is still controversial. However, excluding patients with low-gradient AS would be inappropriate in evaluating severe AS patients with AHF, because transaortic PG tends to decrease with worsening LV pump function. 37 Second, because of the retrospective study design, not all the information regarding biomarkers, hemodynamic parameters and medications possibly related to AHF were available. 38-40 Third, retrospectively confirming the diagnosis of CHF and AHF based on the types of symptoms could potentially lead to incomplete or inaccurate categorization. Therefore, we categorized AHF and CHF according to whether or not hospitalized management was required to avoid the ambiguity of symptom-based categorization.
Our results for NYHA and BNP, which were closely related with the time course and severity of HF, were consistent with the previous large cohorts of AHF. 38,41 Furthermore, we consistently found a dismal prognosis of AHF associated with severe AS in the sensitivity analysis. Therefore, we believe that the patients in each group would appropriately represent the clinical profiles of AHF, CHF, and No HF associated with severe AS. Fourth, the low prevalence of an initial AVR strategy in AHF patients would indicate suboptimal practice non-compliant with current guidelines, although it may well represent real clinical practice. 18 Finally, it should also be acknowledged that the risk factors identified as predisposing to AHF did not disclose causality.
Conclusions
In this observational registry of patients with severe AS, AHF was associated with a dismal prognosis with extremely high mortality rate, which could not be fully resolved by AVR after AHF. Careful management to avoid development of AHF is crucial for patients with severe AS.
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syncope were less often found in the AHF group as compared with the No HF group. This reflects the complex pathophysiology of severe AS in which a narrowed aortic valve causes distinct clinical manifestations such as elevated global LV afterload, decreased tissue perfusion, inappropriate reflex vasodilation and primary cardiac arrhythmia. 15 Very severe AS with Vmax ≥5 m/s and low LVEF were among the echocardiographic parameters related to development of AHF. This result is consistent with previous reports showing that asymptomatic patients with very severe AS and/or low LVEF showed a poor prognosis and supports the current recommendation of AVR in asymptomatic patients with very severe AS and/or low LVEF. [16] [17] [18] Prevalence of anemia in the AHF group was 73%, which was much higher than in the CHF group (55%) or in a previous report on patients with severe AS (57%). 19 The link between anemia and poor outcome in HF is well established. 20,21 Several underlying mechanisms, such as iron deficiency, chronic kidney disease (CKD) and bone marrow dysfunction, have been postulated as the background for anemia in patients with congestive HF. 22-24 Heyde's syndrome could also be an important mechanism for anemia in patients with severe AS. 25 Correction of anemia might be a therapeutic option in the medical management of severe AS.
Our study also identified lower BMI as a risk factor for developing AHF. One possible explanation for this is that lower BMI in our study represented 'cardiac cachexia' in which metabolic, neurohormonal and immune abnormalities evoked by hemodynamic alteration lead to negative energy balance and poor prognosis. 26, 27 Alternatively, the result may be related to the protective effect of adiposity known as the 'obesity paradox', although its validity is still under debate. [28] [29] [30] CKD is a well-established risk factor of HF. 31, 32 In the present study, although an elevated creatinine level showed a trend towards being related to the development of AHF, hemodialysis was a negative predictor for developing AHF. Strict body fluid control under hemodialysis may cancel the potential risk of acute congestion with CKD. Nonetheless, advanced CKD is known to be associated with a rapid progression of AS and poor outcome after surgical AVR or TAVI. 33-36 Further studies of better risk stratification and treatment strategy in this high-risk category are needed.
Decision-Making for Patients With AHF Complicating
Severe AS Advanced age, low BMI, hypertension, prior history of HF, prior history of CABG, liver cirrhosis, moderate to severe lung disease, and TRPG ≥40 mmHg were identified as independent predisposing factors to the choice of a conservative strategy. Some patients with these factors might have been deemed to be inoperable. However, considering the present results of a dismal prognosis in conservatively managed patients, careful assessment of the operative risks and clinical benefits of AVR among these high-risk patients is required. It should be acknowledged that most of the data in the present study were from the period before the introduction of TAVI. Further studies are needed to evaluate whether this less-invasive strategy could improve the prognosis of patients with severe AS complicated by AHF. Figure S1 . Sensitivity analysis. Cumulative incidence of (A) all-cause death and (B) HF hospitalization when patients without coronary artery disease were divided into 2 groups: acute heart failure (AHF) group (n=544) and No AHF group (n=2,137).
